alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Edward H. Deavitt *v.*Frank M. Corry.

May Term, 1916.

Present: Munson, C. J., Watson, Haselton, Powers and Taylor, JJ.

Opinion filed October 30, 1916.

*Account*— Practice *Act•*— Jury *Trial.*

The action of account was not abolished by the practice act, No. 90, Acts of 1915.

A party is not entitled to a trial by jury in an action of account.

Action op Account. Judgment to account and auditor appointed. The defendant moved to dismiss because the action of account was abolished by No. 90, Acts of 1915, because by the provisions of that act the action should be one of contract and the defendant was entitled thereunder to a trial by jury; and because all actions which do not give the defendant a trial by jury were abolished by the act. The defendant also moved to revoke the reference to the auditor, and recall the rule, for the reason that the ease is not one in which the defendant is not entitled to a jury trial, and that the reference was not agreed to by the parties. Heard on the above motions at the September Term, 1915, Washington County, *Waterman,*J., presiding. The motions were overruled, and the defendant excepted. The opinion states the case.

*U. C. Shurtleff*for the defendant.

*W. B. C. Sticlmey, W. A. Lord, John W. Redmond*and *P. L. Laird*for the plaintiff.

Watson, J.

It is urged that the action of account as such is inconsistent with the forms of civil actions specified in section 1 .of the Practice Act of 1915, and consequently it was abolished by section 17, by which all acts and parts of acts inconsistent with that Act were repealed. But this argument loses sight of the provision of section 11, whereby nothing contained in the Act “shall be taken to impair any right or remedy now provided *532by law.” Certainly before the passage of that Act, the action of account was a means provided by law to enforce a right. It was therefore a remedy, and it remains unimpaired.

The foregoing ruling leaves without force the defendant’s contention that he is entitled to a trial by jury. *Hall*v. *Armstrong,*65 Vt. 421, 26 Atl. 592, 20 L. R. A. 366.

*Judgment affirmed and cause remanded.*
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-1264]
 AGENCY: Drug Enforcement Administration, Justice.
 ACTION: Notice of application.
 SUMMARY: AMPAC Fine Chemicals Virginia LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to 
                        **SUPPLEMENTARY INFORMATION**
                         listed below for further drug information.
 DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 14, 2023. Such persons may also file a written request for a hearing on the application on or before November 14, 2023.
 ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to 
                        *https://www.regulations.gov*
                         and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on 
                        *https://www.regulations.gov.*
                         If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.


SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on May 2, 2023, AMPAC Fine Chemicals Virginia LLC., 2820 North Normandy Drive, Petersburg, Virginia 23805-2380, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled substance
Drug
                             code
ScheduleMethylphenidate
1724
IILevomethorphan
9210
IILevorphanol
9220
IIMorphine
9300
IIThebaine
9333
IINoroxymorphone
9668
IITapentadol
9780
II
 The company plans to bulk manufacture the above listed controlled substances for the internal use as intermediates or for distribution to its customers. No other activities for these drug codes are authorized for this registration. Claude Redd, Acting Deputy Assistant Administrator.


[FR Doc. 2023-20003 Filed 9-14-23; 8:45 am] BILLING CODE P
No. 154.

#### Richardson *v.*Brunner et al.

*Frank E. Had-dad, Jr.*and *Robert Hubbard*for petitioner.

Court of Appeals of Kentucky. Certiorari denied.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
      This schedule contains summary financial information (in thousands except
per share data) extracted from Petroleum Heat and Power Co., Inc. and
Subsidiaries financial statements as of December 31, 1997 and is qualified in
its entirety by reference to such financial statements.
</LEGEND>

<MULTIPLIER>                                   1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                              DEC-31-1997
<PERIOD-END>                                   DEC-31-1997
<CASH>                                               2,390  
<SECURITIES>                                             0  
<RECEIVABLES>                                       79,967  
<ALLOWANCES>                                           980  
<INVENTORY>                                         16,285  
<CURRENT-ASSETS>                                   105,124  
<PP&E>                                              73,397  
<DEPRECIATION>                                      42,782  
<TOTAL-ASSETS>                                     247,846  
<CURRENT-LIABILITIES>                               92,688  
<BONDS>                                            288,957  
<PREFERRED-MANDATORY>                               32,489  
<PREFERRED>                                              0  
<COMMON>                                             2,620  
<OTHER-SE>                                        (179,653) 
<TOTAL-LIABILITY-AND-EQUITY>                       247,846  
<SALES>                                            509,751  
<TOTAL-REVENUES>                                   548,141  
<CGS>                                              305,536  
<TOTAL-COSTS>                                      379,748  
<OTHER-EXPENSES>                                   168,481  
<LOSS-PROVISION>                                     1,853  
<INTEREST-EXPENSE>                                  33,813  
<INCOME-PRETAX>                                    (22,164) 
<INCOME-TAX>                                           500  
<INCOME-CONTINUING>                                (22,899) 
<DISCONTINUED>                                           0  
<EXTRAORDINARY>                                          0  
<CHANGES>                                                0  
<NET-INCOME>                                       (22,899) 
<EPS-PRIMARY>                                        (1.06) 
<EPS-DILUTED>                                        (1.06) 
        


</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
SEPTEMBER 30, 2000 FORM 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          15,445
<SECURITIES>                                   918,574
<RECEIVABLES>                                   20,660
<ALLOWANCES>                                     3,530
<INVENTORY>                                          0
<CURRENT-ASSETS>                               951,149
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 951,149
<CURRENT-LIABILITIES>                            6,983
<BONDS>                                        863,666
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            81
<OTHER-SE>                                      80,419
<TOTAL-LIABILITY-AND-EQUITY>                   951,149
<SALES>                                              0
<TOTAL-REVENUES>                                71,130
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                20,812
<LOSS-PROVISION>                                 2,246
<INTEREST-EXPENSE>                              53,704
<INCOME-PRETAX>                                (6,632)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (5,632)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,632)
<EPS-BASIC>                                     (0.70)
<EPS-DILUTED>                                   (0.70)



</TABLE>
#            

# CATERPILLAR FINANCIAL SERVICES CORPORATION

POWERNOTES (R)

With Maturities of 9 months or more from Date of Issue

Registration No.  333-109182

Filed Pursuant to Rule 424 (b) (3)

PRICING SUPPLEMENT NO.  463                                                                   Trade Date:  08/02/04

(To Prospectus Supplement dated November 6, 2003 &

  Prospectus dated October 15,2003)                                                              Issue Date:   08/05/04

The Date of this Pricing SupplementAugust 2, 2004

SUBJECT TO REDEMPTION OR REPAYMENT

 CUSIP                                                                                                                                   Date and terms of redemption or

     or       Stated                                                                   Interest                                       repayment (includingany

Common  Interest                      Price to  Discounts &        Payment     Survivors                  applicable regular or special

  Code      Rate (1)   Maturity  Public (2) Commissions       Frequency       Option  Yes/No     record dates)

14911QVG3  4.5%            08/15/11           100%              1.3%                 Monthly                          YES         NO                                                                                                                                                                                       

                                                                                                                                                                                                                       

Principal                                                                                 1st Payment             Day         

Amount                  Proceeds                  Dealer                           Date                   Count

$1,234,000.00         $1,217,958.00         ABN AMRO Inc.        09/15/04                               30/360    

Original Issue Discount Note:                                                                         Total Amount of OID:

____  Yes                X   No                                                                                  N/A

The interest rates on the PowerNotes (R) may be changed by Caterpillar Financial Services Corporation from time to time, but any such change will not affect the interest rate on any PowerNotes (R) offered prior to the effective date of the change.  Prior to the date of this Pricing Supplement, $127.800 mm principal amount of the PowerNotes (R) were sold at interest rates then in effect.  Subsequent offerings of PowerNotes (R) will be made under the Prospectus Supplement and Prospectus dated October 15,2003.

Expressed as a percentage of aggregate principal amount.  Actual Price to Public may be less, and will be determined by prevailing market prices at the time of purchase as set forth in the confirmation sheet.
#### In the Matter of the New York City Railroad Company.

Reports confirmed.
From: flpastor@comcast.net

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 1:27:22 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Elwood O'Dell

, 3830
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed).                    

*Date:*                         October 19, 2023.                    

*Time:*                         1:00 p.m. to 4:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G76, Rockville, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Marci Scidmore, Ph.D., Scientific Review Officer, Scientific Review Program, Natl. Institute of Allergy & Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G76, Bethesda, MD 20892, (240) 627-3255,                         *marci.scidmore@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 14, 2023.

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-20328 Filed 9-19-23; 8:45 am]

BILLING CODE 4140-01-P
<PAGE>

                                                                    Exhibit 24.1

                               POWER OF ATTORNEY

     KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned officers and
directors of Laidlaw International, Inc., a Delaware corporation, hereby
constitutes and appoints Kevin E. Benson and Jeffrey W. Sanders, and each of
them, as his or her true and lawful attorney or attorneys-in-fact, with full
power of substitution and revocation, for each of the undersigned and in the
name, place and stead of each of the undersigned, to sign on behalf of each of
the undersigned an Annual Report on Form 10-K for the fiscal year ended August
31, 2006 pursuant to Section 13 of the Securities Exchange Act of 1934 and to
sign any and all amendments to such Annual Report, and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting to said attorney or
attorneys-in-fact, and each of them, full power and authority to do so and
perform each and every act and thing requisite and necessary to be done in and
about the premises, as fully to all intents and purposes as the undersigned
might or could do in person, hereby ratifying and confirming all that said
attorney or attorneys-in-fact or any of them or their substitute or substitutes
may lawfully do or cause to be done by virtue thereof.

     This power of attorney may be executed in multiple counterparts, each of
which shall be deemed an original with respect to the person executing it.

     IN WITNESS WHEREOF, the undersigned have hereunto set their hands as of the
26th day of October, 2006.


-------------------------------------   ----------------------------------------
Kevin E. Benson, President, Chief       Richard R. Randazzo, Director
Executive Officer and Director
(Principal Executive Officer)


-------------------------------------   ----------------------------------------
Jeffrey W. Sanders, Vice President      Maria A. Sastre, Director
and Chief Financial Officer
(Principal Financial Officer)


-------------------------------------   ----------------------------------------
John F. Chlebowski, Director            Peter E. Stangl, Director


-------------------------------------   ----------------------------------------
James H. Dickerson, Jr., Director       Carroll R. Wetzel, Jr.


-------------------------------------
Lawrence M. Nagin, Director


by
   ----------------------------------
   Jeffrey W. Sanders, As
   Attorney-in-Fact
## Comments in Response to "Final rule; request for comments" Docket: FAA-2015-3877 Directorate Identifier 2015-SW-039-AD Comments have been received in response to : "Final rule; request for comments," Airworthiness Directive (AD) Docket and Di rec torate Identifier entered above. (Project engineer: Please review any comments to determine 

### if additional action is warranted. Once you have made your de termination, please jill in the commenter(s) name(s) and check the appropriate response below. Include additional information following the appropriate response,

**~f** necessary. Then include your name and the date in the spaces provided , and return it to the AD directorate focal. The FAA has reviewed comment(s) related to the above FAA Docket that we received from: Airbus Helicopters (Please check one) IZI These comments have not been found to contain any information to warrant reconsideration or change of this AD. 

### D These comments have been found to contain information that warrants consideration of additional regulatory action. 

### (SEE Airworthiness Directives Manual F

AA-IR-M-8040.1 FOR ADDITIONAL ACTION.)
Name:

Rev 0 (9/08) Dale 4/2 8/ 2016 Dat e:
(This fol1!Il is p art of the official docket file for this AD action.)